We predicted potential therapeutic candidates that might specifically benefit miR-106b-5p under-active p53-like bladder cancers as well as genomic factors associated with miR-106b-5p under- and overactive p53-like bladder cancers. Here, TP53 is linked to urinary bladder cancer.